Apolipoprotein B levels and related factors in a rural white South African community - the CORIS study

South African Medical Journal

Volumn 86, Issue 4, 1996, Pages 359-364

  Steyn, K ^a   Rossouw, J E ^b   Weight, M J ^a   Fourie, J M ^a   Benade A J S ^a   Jooste, P L ^a   Chalton, D O ^a   Wolmarans, P ^a  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DIAGNOSTIC VALUE; DIET; ELECTROCARDIOGRAPHY; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MALE; MULTIPLE REGRESSION; QUESTIONNAIRE; RISK FACTOR; RURAL AREA; SCREENING; SEX DIFFERENCE; SOUTH AFRICA; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTHROPOMETRY; APOLIPOPROTEINS B; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIET SURVEYS; ELECTROCARDIOGRAPHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RURAL POPULATION; SOUTH AFRICA; TRIGLYCERIDES;

EID: 0029999337     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Thompson G. Apoproteins: determinants of lipoprotein metabolism and indices of coronary risk. Br Heart J 1984; 51: 585-588.
2. Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO. Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis 1984; 4: 79-83.
3. Parra HJ, Arveiler D, Evans AE, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM study. Arterioscler Thromb 1992; 12: 701-707.
4. Sniderrnan AD. Apolipoprotein B and apolipoprotein Al as predictors of coronary artery disease. Can J Cardiol 1988; 4: suppl A, 24A-30A.
5. Stampfer MJ, Sacks FM, Satvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-381.
6. Stein EA. Lipid risk factors and atherosclerosis: what do we measure? Scand J Clin Lab Invest 1990; 198: suppl, 3-8.
7. Marcovina S, Zoppo A, Graziani MS, Vassanelli C, Catapano AL. Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease. Ric Clin Lab 1988; 18: 319-328.
8. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis 1990; 10: 668-671.
9. Sniderman AD, Silberberg J. Is it time to measure apolipoprotein B? Arteriosclerosis 1990; 10: 665-667.
10. Albers JJ, Brunzell JD, Knapp QH. Apoprotein measurements and their clinical application. Clin Lab Med 1989; 9: 137-152.
11. Blank D, Silberberg J, Sniderman AD. Trade-offs on outpoints for the treatment of hyperlipidemia. Coron Artery Dis 1990; 1: 455-459.
12. Tybjaerg-Hansen A, Gallagher J, Vincent J, et al. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990; 80: 235-242.
13. Myant NB, Gallagher JJ, Knight BL, et al. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arterioscler Thromb 1991; 11: 691-703.
14. Rauh G, Keller C, Schuster H, Wolfram G, Zöllner N. Familial defective apolipoprotein B-100: a common cause of primary hypercholesterolemia. Clin Invest 1992; 70: 77-84.
15. Bradshaw D. Dorrington RE, Sitas F. The level of mortality in South Africa in 1985 - what does it tell us about health? S Afr Med J 1992; 82; 237-240.
16. Steyn K, Fourie J, Bradshaw D. The impact of chronic diseases of lifestyle and their major risk factors on mortality in South Africa. S Afr Med J 1992; 82: 227-231.
17. Rossouw JE, Du Plessis JP, Benadé AJS, et al. Coronary risk factor screening in three rural communities: the CORIS baseline study. S Afr Med J 1983; 64: 430-436.
18. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962; 27: 645-658.
19. American Heart Association. Recommendations for Human Blood Pressure Determination by Sphygmomanometers. Dallas: American Heart Association, 1967.
20. Hueck CC, Schlierf G. Nephelometry of apolipoprotein B in human serum. Clin Chem 1979; 25: 221-226.
21. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantization of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982; 23: 1206-1223.
22. Rossouw JE, Steyn K, Berger GMB, et al. Action limits for serum total cholesterol: a statement for the medical profession by an ad hoc committee of the Heart Foundation of Southern Africa. S Afr Med J 1988; 73: 693-700.
23. Blackburn H, Keys A, Simonson E, Rautaharju PM, Punsar S. The electrocardiogram in population studies: a classification system. Circulation 1960; 21: 1160-1175.
24. Bray GA. Definition, measurement and classification of the syndromes of obesity. Int J Obes 1978; 2: 99-112.
25. Durnin JVGA, Rahaman MM. The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr 1967; 21: 681-689.
26. Rossouw JE, Jooste PL, Chalton DO, et al. Community-based intervention: The Coronary Risk Factor Study (CORIS). Int J Epidemiol 1993; 22: 428-438.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
28. Galpin JS. Regression Package PEGPAC (Version 3). Pretoria: SWISK 25, National Research Institute for Mathematical Sciences, CSIR, 1981.
29. Vermaak WJH, Kotze JP, Van der Merwe AM, et al. Epidemiological reference ranges for low-density lipoprotein cholesterol and apolipoprotein B for identification of increased risk of ischaemic heart disease. S Afr Med J 1991; 79: 367-371.
30. Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990; 82: 1574-1594.
31. Rossouw JE, Jooste PL, Steyn K, Benadé AJS. Serum total and high-density lipoprotein cholesterol - reference values obtained in the Coronary Risk Factor Study baseline survey. S Afr Med J 1985; 67: 533-538.
32. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins (a), Al and B and parental history in men with early onset ischaemic heart disease. Lancet 1988; 1: 1070-1073.
33. Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GR. The relation of apolipoproteins A-I and B in children to parental myocardial infarction. N Engl J Med 1986; 315: 721-726.
34. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
35. Austin MA, Breslow JA, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein subclass pattern and risk of myocardial infarction. JAMA 1988; 260: 1917-1921.
36. Donahue RP, Orchard TJ, Stein EA, Kuller LH. Apolipoproteins AI, AII and B in young adults: associations with CHD risk factors. The Beaver County experience. J Chron Dis 1986; 39: 823-830.
37. Nestel PJ. Apoprotein metabolism inhuman obesity. Int J Obes 1982; 6: suppl 1, 105-109.
38. Hagan RD, Parrish G, Licciardone JC. Physical fitness is inversely related to heart disease risk: A factor analytic study. Am J Prev Med 1991; 7: 237-243.
39. Lochen ML, Rasmussen K. The Tromso study: physical fitness, self reported physical activity, and their relationship to other coronary risk factors. J Epidemiol Commun Health 1992; 46: 103-107.
40. Teng B, Sniderman AD, Soutar AK. Metabolic basis of hyperapobetalipoproteinaemia: turnover of apolipoprotein B in low-density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolaemia. J Clin Invest 1986; 77: 663-672.
41. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94: 350-356.